TONIX PHARMACEUTICALS HOLDING CORP. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $1.14 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-10
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $1.14M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $0.00.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $1.28K.
- 2022-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $372.19M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $1.14M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 |
| 2025-09-30 | $1.28K 10-Q · filed 2025-11-10 |
| 2022-03-31 | $372.19M 10-Q · filed 2022-05-09 |
| 2021-09-30 | $90.66M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $3.16B 10-Q · filed 2021-08-09 |
| 2021-03-31 | $5.20B 10-Q · filed 2021-05-10 |
| 2020-12-31 | $131.56M 10-Q · filed 2021-11-08 |
| 2020-09-30 | $681.42M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $95.39M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $151.03M 10-Q · filed 2020-05-12 |
| 2019-03-31 | $39.83M 10-Q · filed 2019-05-13 |
| 2018-06-30 | $705.28M 10-Q · filed 2018-08-13 |
| 2017-09-30 | $63.20M 10-Q · filed 2017-11-06 |
| 2017-06-30 | $22.50M 10-Q · filed 2017-08-11 |
| 2014-12-31 | $0.00 10-K · filed 2015-02-27 |
| 2013-12-31 | $0.00 10-K · filed 2014-03-28 |
| 2012-12-31 | $0.00 10-K/A · filed 2013-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |